From the Guest Editors
Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy—Summary of Advances and Future Directions for Studying These Drugs
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
Novel Checkpoints and Cosignaling Molecules in Cancer Immunotherapy
Radiotherapy and Immune Checkpoint Blockade for Melanoma
Intratumoral Approaches for the Treatment of Melanoma
Adoptive Cell Therapy for Metastatic Melanoma
Novel Targeted Therapies for Metastatic Melanoma
Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma
Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era
Melanoma Brain Metastases
Challenges in Conducting Clinical Research on Patients With Advanced Melanoma